OUR COMPANY

At BioLingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.

BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.

BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.

In terms of diabetes, our lead molecules are an oral "biobetter" of liraglutide and exenatide (GLP-1) in type II diabetes. In addition to that, we are developing a combination product of insulin+GLP1.

We are also exploring the use of low dose IL-2 for early onset juvenile type I diabetes. Low dose IL-2 in animal models has shown to balance Treg and Teff immune cells to reverse or prevent type I diabetes. Especially in children, having an oral therapy will make a difference.

A second area of interest is immuno-therapy, since sublingual administration facilitates targeting the lymphatic system directly.

We have some good data with IL-2 immunotherapy in arthritis, psoriasis, diabetes type 1, peanut allergy and cancer. We believe that this effect is due to altering the balance of Tregs.

Sublingual administration can increase efficacy and/or reduce side-effects compared to administration by injection.

Our technology can also stabilize proteins and peptides to prevent degradation and this is for use in third world countries by :

reducing the need for a cold chain
preventing the risk of infections due to needle handling (e.g. HIV and HCV).

As such, we can “broaden access” for patients in third world countries, which is an important goal for WHO.

Because of the specific properties of our technology, it is applicable to a broad range of molecules, as shown in the diagram below :

Agent of Change - Thomas Ko is a Pioneering Drug Developer and Monash Alumnus - Video